Bruker (NASDAQ:BRKR) Coverage Initiated at Guggenheim

Guggenheim assumed coverage on shares of Bruker (NASDAQ:BRKR - Get Free Report) in a report released on Thursday, MarketBeat Ratings reports. The firm set a "buy" rating and a $72.00 price target on the medical research company's stock. Guggenheim's price target suggests a potential upside of 30.22% from the stock's current price.

A number of other equities analysts have also recently issued reports on the stock. Barclays lowered their price objective on shares of Bruker from $75.00 to $69.00 and set an "overweight" rating for the company in a research report on Wednesday, November 6th. Wells Fargo & Company decreased their price target on shares of Bruker from $78.00 to $75.00 and set an "overweight" rating for the company in a research note on Wednesday, November 6th. Wolfe Research downgraded shares of Bruker from an "outperform" rating to a "peer perform" rating in a research report on Monday, September 30th. Citigroup cut their price target on shares of Bruker from $80.00 to $75.00 and set a "buy" rating for the company in a report on Wednesday, November 6th. Finally, Bank of America upped their price objective on shares of Bruker from $78.00 to $80.00 and gave the company a "buy" rating in a research note on Friday, December 13th. Six equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $74.45.

Bruker Trading Down 0.2 %

Bruker stock traded down $0.09 during mid-day trading on Thursday, hitting $55.29. The stock had a trading volume of 2,548,354 shares, compared to its average volume of 1,124,468. The stock has a 50-day simple moving average of $58.16 and a two-hundred day simple moving average of $62.49. The company has a current ratio of 1.66, a quick ratio of 0.73 and a debt-to-equity ratio of 1.24. Bruker has a 12 month low of $48.07 and a 12 month high of $94.86. The stock has a market capitalization of $8.38 billion, a PE ratio of 26.58, a P/E/G ratio of 4.00 and a beta of 1.18.

Bruker (NASDAQ:BRKR - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 EPS for the quarter, missing the consensus estimate of $0.61 by ($0.01). The company had revenue of $864.40 million for the quarter, compared to analyst estimates of $866.46 million. Bruker had a net margin of 9.41% and a return on equity of 21.52%. The business's revenue for the quarter was up 16.4% on a year-over-year basis. During the same period last year, the company posted $0.74 earnings per share. As a group, sell-side analysts forecast that Bruker will post 2.4 EPS for the current year.

Insider Buying and Selling at Bruker

In related news, CEO Frank H. Laukien purchased 100,000 shares of the business's stock in a transaction dated Monday, November 18th. The stock was acquired at an average price of $50.14 per share, for a total transaction of $5,014,000.00. Following the acquisition, the chief executive officer now directly owns 38,439,563 shares of the company's stock, valued at $1,927,359,688.82. This trade represents a 0.26 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 28.30% of the stock is owned by corporate insiders.

Institutional Trading of Bruker

Institutional investors have recently added to or reduced their stakes in the business. FMR LLC lifted its holdings in Bruker by 21.4% in the third quarter. FMR LLC now owns 14,306,122 shares of the medical research company's stock worth $987,981,000 after acquiring an additional 2,521,904 shares during the last quarter. State Street Corp increased its holdings in shares of Bruker by 9.6% in the 3rd quarter. State Street Corp now owns 3,627,300 shares of the medical research company's stock valued at $250,501,000 after purchasing an additional 318,808 shares during the period. RTW Investments LP grew its stake in Bruker by 1.1% in the third quarter. RTW Investments LP now owns 3,481,119 shares of the medical research company's stock valued at $240,406,000 after purchasing an additional 37,024 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Bruker by 10.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,993,468 shares of the medical research company's stock valued at $137,702,000 after purchasing an additional 193,580 shares in the last quarter. Finally, Marshall Wace LLP raised its position in shares of Bruker by 127.8% in the second quarter. Marshall Wace LLP now owns 1,389,537 shares of the medical research company's stock valued at $88,666,000 after purchasing an additional 779,549 shares during the period. 79.52% of the stock is owned by hedge funds and other institutional investors.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.